Zacks Investment Research cut shares of Atara Biotherapeutics, Inc. (NASDAQ:ATRA) from a buy rating to a hold rating in a report published on Monday.

According to Zacks, “Atara Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. It is focused on developing therapeutics for serious unmet medical needs, with an initial focus on muscle wasting conditions and oncology. The company’s lead programs are focused on myostatin and activin, members of the TGF-beta family of proteins that have demonstrated the potential to have therapeutic benefit in a number of clinical indications. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. Atara Biotherapeutics, Inc. is headquartered in Brisbane, California. “

Other equities research analysts have also recently issued research reports about the stock. BidaskClub cut shares of Atara Biotherapeutics from a hold rating to a sell rating in a research report on Tuesday, August 22nd. Canaccord Genuity set a $47.00 target price on shares of Atara Biotherapeutics and gave the company a buy rating in a research report on Monday, August 7th. ValuEngine cut shares of Atara Biotherapeutics from a sell rating to a strong sell rating in a research report on Tuesday, August 1st. Jefferies Group LLC reissued a buy rating and set a $30.00 target price on shares of Atara Biotherapeutics in a research report on Thursday, June 22nd. Finally, William Blair reissued an outperform rating on shares of Atara Biotherapeutics in a research report on Monday, June 26th. Four equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. Atara Biotherapeutics currently has an average rating of Hold and an average target price of $23.60.

Shares of Atara Biotherapeutics (NASDAQ:ATRA) opened at 15.75 on Monday. The company’s market cap is $481.30 million. The company’s 50 day moving average is $14.87 and its 200 day moving average is $15.88. Atara Biotherapeutics has a 12 month low of $11.80 and a 12 month high of $23.00.

Atara Biotherapeutics (NASDAQ:ATRA) last posted its earnings results on Monday, August 7th. The biotechnology company reported ($0.94) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.89) by $0.05. On average, equities research analysts predict that Atara Biotherapeutics will post ($3.89) EPS for the current fiscal year.

COPYRIGHT VIOLATION NOTICE: “Atara Biotherapeutics, Inc. (ATRA) Stock Rating Lowered by Zacks Investment Research” was originally reported by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally copied and republished in violation of international copyright & trademark laws. The original version of this piece can be accessed at https://www.watchlistnews.com/atara-biotherapeutics-inc-atra-stock-rating-lowered-by-zacks-investment-research/1535962.html.

In other news, EVP Mitchall G. Clark sold 3,021 shares of the stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $14.33, for a total value of $43,290.93. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Isaac E. Ciechanover sold 4,400 shares of the stock in a transaction on Wednesday, August 23rd. The stock was sold at an average price of $13.54, for a total transaction of $59,576.00. Following the completion of the sale, the chief executive officer now owns 737,767 shares in the company, valued at approximately $9,989,365.18. The disclosure for this sale can be found here. In the last ninety days, insiders sold 46,109 shares of company stock valued at $673,304. Corporate insiders own 16.10% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in ATRA. Neuberger Berman Group LLC raised its stake in Atara Biotherapeutics by 11.5% in the first quarter. Neuberger Berman Group LLC now owns 836,515 shares of the biotechnology company’s stock worth $17,190,000 after buying an additional 86,375 shares during the last quarter. American International Group Inc. raised its stake in Atara Biotherapeutics by 7.1% in the first quarter. American International Group Inc. now owns 14,304 shares of the biotechnology company’s stock worth $294,000 after buying an additional 948 shares during the last quarter. Tokio Marine Asset Management Co. Ltd. acquired a new stake in Atara Biotherapeutics during the first quarter worth $555,000. Parametric Portfolio Associates LLC raised its stake in Atara Biotherapeutics by 62.6% in the first quarter. Parametric Portfolio Associates LLC now owns 25,389 shares of the biotechnology company’s stock worth $522,000 after buying an additional 9,774 shares during the last quarter. Finally, Eagle Asset Management Inc. raised its stake in Atara Biotherapeutics by 14.1% in the first quarter. Eagle Asset Management Inc. now owns 1,267,609 shares of the biotechnology company’s stock worth $26,049,000 after buying an additional 156,911 shares during the last quarter. Hedge funds and other institutional investors own 82.95% of the company’s stock.

Atara Biotherapeutics Company Profile

Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.